Core Viewpoint - Altria Group, Inc. is expected to report a decline in revenues for Q2 2025, while earnings are projected to show growth compared to the previous year [1][9]. Revenue and Earnings Estimates - The Zacks Consensus Estimate for Q2 revenues is $5.2 billion, reflecting a 1.7% decrease from the same period last year [1]. - The consensus estimate for earnings per share (EPS) has increased to $1.37, indicating a 4.6% growth year-over-year [1][9]. Earnings Performance and Predictions - Altria has a trailing four-quarter average earnings surprise of 1.3%, with the last quarter's earnings exceeding the Zacks Consensus Estimate by 5.1% [2]. - The company currently has an Earnings ESP of +1.03% and a Zacks Rank of 3 (Hold), suggesting a potential earnings beat [4][3]. Factors Influencing Q2 Earnings - Regulatory pressures, particularly the ITC's exclusion order on NJOY ACE, have negatively impacted Altria's smoke-free product portfolio [5]. - The cigarette business is facing volume pressures due to consumer downtrading and competition from illicit flavored disposable vapes [5]. - Despite these challenges, Altria's strong pricing power and cost control measures are expected to support profitability [6][7]. Stock Performance - Over the past three months, Altria's stock has increased by 2.6%, slightly below the Zacks Tobacco industry's growth of 2.7% and significantly trailing the S&P 500's 15.5% rise [8]. - Altria's stock performance has outpaced Philip Morris International, which declined by 6.8%, but underperformed Turning Point Brands and British American Tobacco [8]. Valuation Analysis - Altria shares are trading at a forward 12-month price-to-earnings (P/E) ratio of 10.96, below the industry average of 14.48, indicating attractive value for investors [11]. - Compared to key competitors, Altria's P/E ratio is significantly lower than Philip Morris International (20.11) and Turning Point Brands (21.54), while being comparable to British American Tobacco (10.94) [13]. Investment Outlook - Altria faces a mixed backdrop with regulatory challenges and volume pressures, but resilient pricing power and disciplined cost control may provide stability [14]. - Investors may consider holding positions or selectively adding to their investments, while monitoring management's updates on product pipeline and strategic execution [14].

Core Insights - Robert Half International Inc. (RHI) reported second-quarter fiscal 2026 results with earnings and revenues exceeding the Zacks Consensus Estimate, yet the market reaction was negative, leading to a 6.1% decline in stock price since the earnings release on July 23 [1] - Quarterly earnings were 41 cents per share, surpassing estimates by 2.5% but reflecting a year-over-year decline of 37.9% [1][7] - Revenues totaled $1.37 billion, exceeding the consensus by 1.4% but down 7% year over year [1][7] Financial Performance - Talent Solutions revenues were $874.521 million, down 11.3% year over year and below the estimate of $914.2 million; U.S. Talent Solutions revenues were $668 million, a decrease of 11% year over year [4] - Protiviti revenues reached $495.2 million, up 2% year over year but below expectations; U.S. Protiviti revenues decreased by 1% to $396 million, while non-U.S. revenues increased by 11% to $99 million [5] - The adjusted gross profit was $522.3 million, down 9.9% year over year, with a gross profit margin of 39.1%, a decline of 210 basis points [8] Market Comparison - RHI's shares have depreciated 37.2% over the past year, contrasting with a 28.4% decline in the Staffing Firms industry and a 17.4% rise in the Zacks S&P 500 composite [2] Guidance and Projections - For Q3 2025, RHI expects revenues between $1.31 billion and $1.41 billion, with an EPS forecast of 37 to 47 cents, below the current consensus estimate of 52 cents [10] - The company anticipates 64.2 billing days in Q3 2025, slightly up from 64.1 billing days in Q3 2024 [11] - Capital expenditures for Q3 are projected between $15 million and $25 million, with full-year estimates for 2025 ranging from $75 million to $90 million [11]

Core Viewpoint - IDEX Corporation (IEX) is expected to report second-quarter 2025 results on July 30, with a consensus estimate for revenues at $857.2 million, reflecting a 6.2% year-over-year increase, while adjusted earnings are projected at $2.00 per share, indicating a 2.9% decline from the previous year [1][2][10] Group 1: Revenue and Earnings Estimates - The consensus estimate for revenues is $857.2 million, which is a 6.2% increase from the prior-year quarter [2] - The adjusted earnings estimate is $2.00 per share, showing a 2.9% decline compared to the same quarter last year [2] Group 2: Segment Performance - The Health & Science Technologies (HST) segment is anticipated to generate revenues of $356 million, marking a 17.1% year-over-year increase due to strong momentum in energy transition and analytical instrumentation [3] - The Fire & Safety/Diversified Products (FSDP) segment is expected to report revenues of $188.4 million, up 1.6% year over year, driven by strong demand in OEM and integrated solutions [4] - The Fluid & Metering Technologies (FMT) segment is projected to see revenues of $312.2 million, reflecting a 2.2% decline year over year, primarily due to softness in the chemical and agriculture markets [5] Group 3: Recent Acquisitions - The acquisition of Mott Corp. in September 2024 and STC Material Solutions in December 2023 has expanded IDEX's capabilities in applied materials science technology, likely enhancing performance in high-value end markets [6][10] Group 4: Earnings Prediction - IDEX has an Earnings ESP of +0.25%, with the Most Accurate Estimate at $2.01 per share, suggesting a potential earnings beat [9] - The company currently holds a Zacks Rank of 2, indicating a favorable outlook for earnings performance [9]

Core Insights - Bloom Energy (BE) is set to release its second-quarter 2025 results on July 31, with a previous earnings surprise of 142.9% [1] Group 1: Earnings Expectations - The Zacks Consensus Estimate for Bloom Energy's earnings is projected to be breakeven, while revenues are expected to reach $381.39 million, reflecting a year-over-year increase of 13.6% [5][9] Group 2: Factors Influencing Performance - The company's earnings are anticipated to benefit from increasing energy demand from data centers, with its on-site power generation solutions enhancing energy efficiency and sustainability [3][9] - Bloom Energy's ongoing projects in South Korea, particularly through its partnership with SK ecoplant, are expected to contribute positively to its top line, reinforcing its market leadership in the hydrogen economy and electricity generation [4][9] - The expansion of Bloom Energy's domestic and international commercial capabilities is likely to further support its earnings growth [2][9] Group 3: Earnings Prediction Model - The current model does not predict an earnings beat for Bloom Energy, as the Earnings ESP stands at 0.00% and the company holds a Zacks Rank of 3 (Hold) [6][7]

Core Insights - FTI Consulting, Inc. (FCN) reported strong second-quarter 2025 results with earnings and revenues exceeding the Zacks Consensus Estimate, but the stock price remained flat post-earnings release [1][7] - Adjusted EPS was $2.13, beating estimates by 14% but down 9% year over year; total revenues were $943.7 million, surpassing estimates by 3.6% but declining 0.6% year over year [1][7] Segment Performance - Technology revenues decreased by 27.9% year over year to $83.6 million, primarily due to lower demand for M&A-related "second request" services [3] - Economic Consulting revenues fell 17% year over year to $191.7 million, driven by reduced demand for M&A-related antitrust services, partially offset by higher realized bill rates [3] - Corporate Finance & Restructuring revenues increased by 9% year over year to $379.2 million, attributed to higher demand for restructuring services and increased bill rates [4] - Strategic Communications revenues rose by 20.8% year over year to $102.7 million, mainly due to an increase in pass-through revenues and demand for corporate reputation services [5] - Forensic and Litigation Consulting revenues grew by 10% year over year to $186.5 million, supported by higher realized bill rates for risk and investigations services [8] Financial Metrics - Adjusted EBITDA was $111.6 million, down 3.7% year over year, with an adjusted EBITDA margin declining by 410 basis points to 8.7% [9] - The company ended the quarter with cash and cash equivalents of $152.8 million, down from $226.4 million in the prior quarter, and generated $55.7 million from operating activities [10] Guidance - FCN projects full-year 2025 revenues between $3.66 billion and $3.76 billion, with EPS expected to range from $7.24 to $7.84 [11] - The company anticipates additional capital expenditures of $29 million to $36 million for the remainder of 2025 [12]

Core Insights - Everest Group, Ltd. (EG) is anticipated to show revenue growth but a decline in earnings for Q2 2025, with revenues expected at $4.40 billion, reflecting a 4.1% increase year-over-year [1] - The consensus estimate for earnings per share is $15.14, indicating a 10.1% decline compared to the previous year [2] Revenue and Earnings Estimates - The Zacks Consensus Estimate for EG's second-quarter revenues is $4.40 billion, marking a 4.1% growth from the prior year [1] - The earnings estimate has decreased by 0.06% over the last 30 days, suggesting a year-over-year decline of 10.1% [2] Earnings Prediction Model - The model indicates a potential earnings beat for Everest Group, supported by a positive Earnings ESP of +0.85% and a Zacks Rank of 3 (Hold) [3][4] Segment Performance - The Reinsurance and Insurance segments are expected to drive premium growth, with net written premiums projected to rise 6.6% to $4.3 billion [5][11] - The Insurance segment is likely to see premiums earned increase by 0.6% to $915.1 million, while the Reinsurance segment is expected to improve by 12.6% to $3 billion [6][7] Investment Income and Underwriting Profitability - Net investment income is anticipated to be $475.6 million, slightly below the Zacks Consensus Estimate of $495 million, influenced by higher income from fixed maturity investments [8] - The combined ratio is expected to improve to 85.4, indicating enhanced underwriting profitability due to rate increases and exposure growth [9][11] Claims and Expenses - Total claims and expenses are projected to rise by 3.2% to $3.5 billion, driven by higher incurred losses and other underwriting expenses [12]

Core Viewpoint - Xcel Energy (XEL) is expected to report its second-quarter 2025 results on July 31, following a previous quarter with a negative earnings surprise of 9.7% [1] Factors Impacting Q2 Performance - The residential electric and natural gas bills in Xcel Energy's operating regions are lower than the national average, attracting new customers and positively impacting top-line performance [2] - Increased demand from data centers, the rise of electric vehicles, and regional economic growth are also anticipated to contribute positively to earnings [3] - However, higher operation and maintenance expenses, along with increased depreciation and interest costs, may offset some of these positive factors [3] Q2 Expectations - The Zacks Consensus Estimate for earnings is set at 62 cents per share, reflecting a year-over-year increase of 14.8% [4] - Revenue is projected to reach $3.31 billion, indicating a year-over-year improvement of 9.3% [4] Earnings Prediction - The earnings model predicts a potential earnings beat for Xcel Energy, supported by a positive Earnings ESP of +1.76% and a Zacks Rank of 3 (Hold) [5][6] Other Industry Considerations - Eversource Energy (ES) and IDACORP (IDA) are also expected to report earnings beats, with respective Earnings ESPs of +0.26% and +2.34% [7][10] - Consolidated Edison (ED) is projected to have an Earnings ESP of +3.88% [10]

Core Viewpoint - Incyte Corporation (INCY) is expected to exceed expectations in its second-quarter 2025 earnings report, with revenue estimates at $1.15 billion and earnings at $1.40 per share [1]. Factors Likely to Influence INCY's Q2 Results - Incyte's primary revenue source is from its lead drug, Jakafi (ruxolitinib), with strong sales anticipated across all approved indications, although competition may limit growth [2]. - The Zacks Consensus Estimate for Jakafi's sales in Q2 is $744 million, with higher royalties expected from Novartis due to increased Jakavi sales outside the U.S. [3][4]. Sales Performance of Other Drugs - Opzelura's sales are projected to reach $149 million, driven by new patient starts and strong uptake in the EU [8]. - Additional contributions to revenue are expected from other drugs like Minjuvi, Pemazyre, and Iclusig, with respective sales estimates of $34.25 million, $20.24 million, and $28.99 million [11]. Recent Developments - The FDA approved Monjuvi for a new cancer indication, which is likely to enhance its sales performance [10]. - Niktimvo, launched in Q1 2025, recorded $13.6 million in sales, and further updates on its launch activities are anticipated [12][13]. Earnings Surprise History - Incyte has a mixed earnings surprise history, with one earnings beat in the last four quarters and an average negative surprise of 82.37% [14]. Earnings Predictions - The Earnings ESP for Incyte is +1.43%, indicating a potential earnings beat, supported by a Zacks Rank of 3 [15][16].

Core Insights - Revvity, Inc. (RVTY) is expected to report second-quarter 2025 results on July 28, with a history of earnings surprises averaging 7.71% over the last four quarters [2][4][14] Q2 Estimates - The Zacks Consensus Estimate for revenues is $711.3 million, reflecting a 2.8% increase year over year, while earnings are estimated at $1.14 per share, indicating a 6.6% decline year over year [3] - Revvity anticipates organic revenue growth of 2% to 4%, translating to total revenues between $700 million and $715 million, with gross margins expected around 60% due to tariff impacts [4][10] Diagnostics Segment - The Diagnostics segment grew 5% organically in Q1 2025, driven by high-single-digit growth in immunodiagnostics and strong performance in reproductive health [5][6] - For Q2 2025, the Diagnostics segment is projected to contribute significantly, with revenues estimated at $388.4 million, up 2.8% year over year [7][10] Life Sciences Segment - The Life Sciences segment experienced 2% organic growth in Q1 2025, supported by strong reagent demand and over 20% growth in the Signals Software business [8] - Revenues for the Life Sciences segment are estimated at $321.7 million, reflecting a 2.5% increase year over year, despite pressures from weak academic demand for instrumentation [9][10] Other Factors - Revvity's collaboration with Genomics England aims to enhance newborn genomic screening, supporting momentum in the Diagnostics segment [11] - The launch of the IDS i20 analytical platform by EUROIMMUN is expected to drive incremental revenue in the Diagnostics segment during Q2 [12] - Tariff-related headwinds are anticipated to peak in Q2, but management has implemented mitigation strategies expected to take effect in the second half of the year [13]

Core Insights - Unum Group (UNM) is expected to report second-quarter 2025 earnings on July 29, with anticipated improvements in both revenue and earnings compared to the previous year [1][2] - The Zacks Consensus Estimate for UNM's first-quarter revenues is $3.32 billion, reflecting a 2.4% growth year-over-year [1] - The consensus estimate for earnings is $2.23 per share, indicating a year-over-year increase of 3.2% despite a recent downward adjustment of 8 cents in the past 30 days [2] Earnings Prediction Model - The current Earnings ESP for UNM is -0.79%, as the Most Accurate Estimate of $2.21 is lower than the Zacks Consensus Estimate of $2.23, indicating uncertainty in predicting an earnings beat [3] - UNM holds a Zacks Rank of 3, suggesting a hold position [4] Factors Influencing Q2 Results - Premium income is projected at $2.7 billion, representing a 3% increase from the previous year, driven by favorable persistency and improved sales across operating segments [5] - Net investment income is estimated at $543.7 million, supported by higher miscellaneous investment income and increased invested assets, compared to the Zacks Consensus Estimate of $524 million [6] - Performance in Unum U.S. and Colonial Life is expected to benefit from higher premium income and improved benefit experiences across various product lines [7] Segment Revenue Estimates - Unum US operating revenues are estimated at $2 billion, while Colonial Life is projected at $501 million [8] - Unum International is expected to generate $290.2 million in operating revenues, benefiting from expansion and improved performance in its product lines [8] Expense Considerations - Total benefits and expenses are anticipated to reach $2.8 billion, influenced by increased policy benefits, commissions, and other costs [10] - Continued share buybacks are likely to positively impact the bottom line [10]